Association between XRCC3 rs861539(Thr241Met) polymorphism and thyroid cancer risk (a Meta-analysis)

Yayun Wu
FuYang Cancer Hospital

Yun Ren (✉ 825269275@qq.com)
TaiHe County People's Hospital

Zhimin Cao
FuYang Cancer Hospital

Kai Zhang
FuYang Cancer Hospital

Xiaoqiang Dong
TaiHe County People's Hospital

Qinjing Lv
TaiHe County People's Hospital

Bowen Wang
TaiHe County People's Hospital

Wei Yao
TaiHe County People's Hospital

Research Article

Keywords: Thyroid cancer, XRCC3, rs861539, polymorphism, meta-analysis

DOI: https://doi.org/10.21203/rs.3.rs-285788/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objective To explore the association between single nucleotide polymorphism (SNP) in the XRCC3 rs861539(Thr241Met) locus and thyroid cancer risk.

Methods Studies investigating the association between SNP in the XRCC3 gene and thyroid cancer susceptibility were retrieved from the PubMed, Embase, Web of Science, CNKI (Chinese National Knowledge Infrastructure), WanFang, and CBM (China Biology Medicine) databases. Eligible studies were screened according to inclusion/exclusion criteria and principles of quality evaluation. Meta-analysis was performed using Stata 14.0 software. Odds ratios with their corresponding 95% confidence intervals were pooled to assess the association between SNP in the XRCC3 gene rs861539 locus and thyroid cancer susceptibility.

Results 10 articles (11 studies) were eligible for this meta-analysis. Meta-analysis results were shown as follows: No significant association was found between XRCC3 rs861539 polymorphism and thyroid cancer risk in Dominant and Overdominant models:
Dominant model: CT+TT vs CC, OR=1.231, 95% CI(0.998, 1.474); Overdominant model: CT vs TT+CC, OR=1.05, 95% CI(0.94, 1.18).
Significant associations were found in Recessive and Allelic models:
Recessive model: TT vs CC+CT, OR=1.632, 95% CI(1.349, 1.974); Allelic model: T vs C: OR=1.263, 95% CI(1.091, 1.462).

Conclusion The results of this study suggest that the XRCC3 rs861539(Thr241Met) polymorphism may be associated with an increased thyroid cancer risk in overall population, and a tendency for significantly increased thyroid cancer risk in TT(Met/Met) genotype population.

Introduction

Thyroid cancer (TC) is one of the most common endocrine malignancies in human, which accounts for 3.1% of all new cancer cases and 0.4% of cancer deaths worldwide annually\[1\]. The incidence of thyroid cancer has been increasing rapidly in recent years, and the largest increase in incidence of all cancers was seen for thyroid cancer in China\[2\]. The reason might due to the rapid development of imaging detection technologies and increasing awareness of people's health\[3\], especially considering that thyroid cancer mortality remained stable at a rate of approximately 0.5 cases per 100000 persons\[4\]. Thyroid cancers are divided into four main sub-types(papillary, follicular, medullary, and undifferentiated cancers)\[5\].To date, the mechanism of thyroid carcinogenesis remains incompletely understood, and the only well-established risk factor for thyroid cancer might be exposure to ionizing radiation\[6\].

DNA damaging which caused by ionizing radiation may lead to mutations, genomic instability. The XRCC3(X-ray repair cross-complementing group 3) located on chromosome 14q32.3 is structurally and functionally related to the RAD51 gene\[7\], which encodes a member of the RecA/Rad51-related protein family involved in homologous recombination to preserve chromosome stability and repair DNA damage caused by endogenous and exogenous factors\[8\]. Over the past decade, several studies have reported the association regarding XRCC3 rs861539 polymorphism and thyroid cancer risk\[9-14\], however, the results remained inconclusive due to some potential limitations, such as small sample size, different ethnicity, and phenotypic heterogeneity. Therefore, this meta-analysis was conducted to make this discrepancy clear and to create a comprehensive picture of the association between XRCC3 rs861539 polymorphism and thyroid cancer susceptibility.

1. Materials And Methods

1.1 Literature selection criteria

1.1.1 Inclusion criteria

(1) Case–control or cohort studies were conducted to investigate the association between XRCC3 rs861539(Thr241Met) polymorphism and thyroid carcinoma risk; (2) studies with full text articles; (3) English or Chinese articles; (4) providing available genotype data for at least one genetic model. (4) all thyroid cancer cases must be pathologically confirmed.

1.1.2 Exclusion criteria

(1) Meeting abstracts, reviews, and animal experiments; (2) only case population; (3) studies with overlapping data; (4) not for cancer research

1.2 Search strategy

A comprehensive computerized literature search of the PubMed, EmBase, Web of Science, China National Knowledge Infrastructure (CNKI), WanFang, and China Biology Medicine databases up to February 2021 was conducted. The search strategy used the following keywords: XRCC3 or rs861539 or X-ray repair cross-complementing group 3 or Thr241Met or C241T or T241M and thyroid carcinoma or thyroid cancer. Furthermore, to retrieve as many articles meeting our criteria as possible, we also investigated the reference literature listed in the articles we had found.
1.3 Data extraction

Literature selection was completed by two investigators independently. For conflicting evaluations, a third reviewer assessed the articles until an agreement was reached. The following information was recorded for each study: first author, year of publication, country, ethnicity, number of cases, number of controls, genotype distribution, genotyping methods (all of the data are shown in Table 1).

1.4 Assessment of the risk of bias in the included literature

The Newcastle–Ottawa quality assessment Scales (NOS) was used to assess all case-control studies included in our present meta-analysis. The NOS contains 8 items, and the possible scores is ranged from 0 up to 9, a study is considered high quality if it gets more than 5 scores. Finally, the quality of all the studies included in this meta-analysis was acceptable.

1.5 Statistical analysis

All statistical analysis were carried out using the STATA version 14.0 software (StataCorp, College Station, TX, USA). \( \chi^2 \) analysis with a significance level of \( P<0.05 \) was used to evaluate whether rs861539(Thr241Met) polymorphism distribution of the XRCC3 gene in controls fits HWE (Hardy Weinberg equilibrium). Heterogeneity among the studies in each genetic model was assessed by using Cochran's \( Q \) and \( I^2 \) statistics. A \( P \) value of <0.05 or \( I^2 \) value of >50% was interpreted as having significant heterogeneity. Random effect model was used to summarize all the studies. Otherwise, the fixed effects model was chosen. We used odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) to evaluate relationships between rs861539(Thr241Met) polymorphism and any predisposition to thyroid cancer. Publication bias was assessed by performing Peters' test. The significance of the intercept was determined by the t-test suggested by Peters, where \( P<0.05 \) was considered representative of statistically significant publication bias. For all analyses, statistically significance was assumed at \( P<0.05 \), unless otherwise stated.

2. Results

2.1 Retrieval of studies and their characteristics

The initial search strategy resulted in the identification of 96 records (PubMed, \( N = 19 \); Web of Science, \( N = 23 \); Embase, \( N = 20 \); CNKI, \( N = 23 \); CBM, \( N = 2 \); Wanfang, \( N = 9 \)), of which 85 were excluded after reading the title, abstract, full text. One relevant article was excluded by reason of the low quality evaluation\(^{[15]}\). Finally, 10 articles (11 studies) met the inclusion criteria (the detailed selection process has been illustrated in Fig. 1), consisting of 1 mixed, 5 Asian and 5 Caucasian populations, and these included eligible studies published between 2005 and 2019. Extracted data of eligible studies are summarized in Table 1. The genotype frequency among cases and controls for rs861539 polymorphism are also shown in Table 1. The distributions of genotype in the control group were in HWE for most studies (\( P > 0.05 \)).

Table 1 General information of the included studies
| Author          | Year | Ethnicity | Case/Control | Cases | Controls | HWE | NOS | Genotyping |
|-----------------|------|-----------|--------------|-------|----------|-----|-----|------------|
| Sturgis[16]     | 2005 | Mixed     | 134/161      | 45    | 69       | 20  | 83  | 60         |
| Ni[12]          | 2006 | Asians    | 191/201      | 179   | 12       | 0   | 181 | 20         |
| Siraj[14]       | 2008 | Asians    | 37/227       | 18    | 12       | 7   | 97  | 105        |
| Akulevich1[13]  | 2009 | Caucasians| 120/198      | 53    | 51       | 16  | 82  | 89         |
| Akulevich2[13]  | 2009 | Caucasians| 132/398      | 55    | 65       | 12  | 161 | 45         |
| Bastos[17]      | 2009 | Caucasians| 109/214      | 39    | 44       | 26  | 71  | 114        |
| Fayaz[18]       | 2013 | Caucasians| 161/182      | 71    | 76       | 14  | 101 | 68         |
| Yuan[19]        | 2016 | Asians    | 183/367      | 95    | 64       | 24  | 232 | 115        |
| Sarwar[20]      | 2017 | Asians    | 456/400      | 277   | 109      | 70  | 273 | 85         |
| Yan[21]         | 2016 | Asians    | 275/403      | 143   | 97       | 35  | 255 | 126        |
| Santos[22]      | 2019 | Caucasians| 106/209      | 36    | 44       | 26  | 70  | 112        |

RFLP: Restriction fragment length polymorphism

ARMS-PCR: Allele-specific polymerase chain reaction

HWE = Hardy-Weinberg Equilibrium test

NOS: Newcastle–Ottawa quality assessment Scales

### 2.2 Quantitative synthesis and sensitivity analysis

The relationship between rs861539 polymorphism and thyroid cancer is summarized in Table 2. Significant associations were observed between rs861539 polymorphism and the risk of TC under recessive and allelic models (Recessive model: TT vs CT+CC, OR=1.632, 95% CI (1.349, 1.974); Allelic model: T vs C, OR=1.263, 95% CI (1.091, 1.462)). The aim of sensitivity analysis was to assess the effect of individual studies on the consistency of the pooled ORs by omitting a single study in each order under all genetic models (as is shown in Table 3). The results suggested that no individual study significantly affected the pooled ORs in all genetic models.

| Genetic models     | Genotype Comparison | No. of included studies | Case | Control | Heterogeneity test | Selected models | Meta-analysis results | Peters test |
|--------------------|---------------------|-------------------------|------|---------|-------------------|----------------|-----------------------|-------------|
| Dominant model     | CT+TT vs CC         | 11                      | 1904 | 2960    | 55.1%             | Random         | OR(95% CI)            | P           |
| Recessive model    | TT vs CT+CC         | 10                      | 1713 | 2759    | 34.4%             | Fixed          | 1.632(1.349, 1.974)   | <0.001      |
| Allele model       | T vs C              | 11                      | 3808 | 5920    | 54.2%             | Random         | 1.263(1.091, 1.462)   | <0.001      |
| Overdominant model | CT vs TT+CC         | 11                      | 1904 | 2960    | 60.0%             | Random         | 0.994(0.805, 1.227)   | 0.954       |

Table 3 Sensitivity analysis
### 2.3 Subgroup analysis

We conducted subgroup analyses by different ethnicities (Asians/Caucasians/Mixed) (as is shown in Table 4), and grouping studies by Asians/Caucasians/Mixed populations could lead to heterogeneities decreased partly. Since we could not confirm that various ethnicities be the source of heterogeneity. To be specific, we found that rs861539 (Thr241Met) polymorphism may be significantly associated with an increased thyroid cancer risk in recessive genetic model among Asians/Caucasians populations (recessive model: TT vs CC+CT, Asians/OR=1.964, 95% CI(1.487, 2.595); Caucasians/ OR=1.373, 95% CI(1.032,1.827)), and significantly associated with an increased thyroid cancer risk in allelic genetic model among Asians and Mixed populations(Asians/OR=1.378, 95% CI(1.108,1.715);Mixed/OR=1.614, 95% CI (1.147,2.270)). However, no significant association between rs861539(Thr241Met) polymorphism and thyroid cancer risk was observed in Caucasians in allelic model(OR=1.107, 95%CI (0.959,1.279)). Lastly, no significant association between rs861539(Thr241Met) polymorphism and thyroid cancer risk was observed in other genetic models among Asians/Caucasians populations.

#### Table 4 Subgroup analysis of ethnicity

| Genetic models         | Ethnicity   | No. of included studies | OR(95% CI)             | P value   | I² / P value | Model       |
|------------------------|-------------|-------------------------|------------------------|-----------|--------------|-------------|
| Dominant model         | Overall     | 11                      | 1.231(0.998,1.474)     | 0.053     | 55.1% / 0.014 | Random      |
| T+T vs CC              | Caucasians  | 5                       | 1.045(0.856,1.277)     | 0.664     | 15.8% / 0.314 | Fixed       |
|                        | Asians      | 5                       | 1.284(0.977,1.688)     | 0.073     | 53.4% / 0.073 | Random      |
|                        | Mixed       | 1                       | 2.105(1.311,3.379)     | 0.002     | /             | /           |
| Recessive model        | Overall     | 10                      | 1.632(1.349, 1.974)    | <0.001    | 34.4% / 0.133 | Fixed       |
| T vs CT+CC             | Caucasians  | 5                       | 1.373(1.032,1.827)     | 0.03      | 47.8% / 0.105 | Fixed       |
|                        | Asians      | 4                       | 1.964(1.487,2.595)     | <0.001    | 0.00% / 0.403 | Fixed       |
|                        | Mixed       | 1                       | 1.394(0.704,2.758)     | 0.340     | /             | /           |
| Allelic model          | Overall     | 11                      | 1.263(1.091,1.462)     | 0.002     | 54.2% / 0.016 | Random      |
| T vs C                 | Caucasians  | 5                       | 1.107(0.959,1.279)     | 0.166     | 13.6% / 0.327 | Fixed       |
|                        | Asians      | 5                       | 1.378(1.108,1.715)     | 0.004     | 52.9% / 0.075 | Random      |
|                        | Mixed       | 1                       | 1.614(1.147,2.270)     | 0.006     | /             | /           |
| Overdominant model     | Overall     | 11                      | 0.994(0.805,1.227)     | 0.954     | 60.0% / 0.005 | Random      |
| CT vs TT+CC            | Caucasians  | 5                       | 0.885(0.633,1.238)     | 0.477     | 65.0% / 0.022 | Random      |
|                        | Asians      | 5                       | 1.078(0.898,1.293)     | 0.421     | 35.6% / 0.184 | Fixed       |
|                        | Mixed       | 1                       | 1.787(1.122,2.847)     | 0.015     | /             | /           |

### 2.4 Publication bias

Publication bias was assessed using Harbord's tests for each genetic model, and there was no evidence of publication bias for all of the genetic models (as is shown in Table 2).
3. Discussion

The X-ray repair cross-complementing group 3 gene (XRCC3) belongs to a family of genes responsible for repairing DNA double-strand breaks \([23]\), and it encodes a 346 amino acid polypeptide that participates in DNA double-strand break repair \([24]\). Among several SNPs identified in the XRCC3 gene, the most extensively studied is Thr241Met on exon 7 (rs861539), which can influence the ability to repair DNA \([25]\). The rs861539 (C>T) polymorphism is a nonsynonymous substitution (C→T) resulting in an amino acid change from threonine to methionine at position 241 (Thr241Met) \([26, 27]\). In the past decade, numerous studies have investigated the potential biological significance of the XRCC3 rs861539 polymorphism, and it has been implicated as a causative risk factor for the development of different types of malignancies. The malignancy types included breast cancer \([7, 32, 33]\), lung cancer \([34]\), osteosarcoma \([25]\), melanoma \([36]\), thyroid cancer \([14, 16]\). However, the correlation between XRCC3 rs861539 polymorphism and thyroid cancer risk still remained controversial \([9, 13, 16, 17]\). To derive a more precise estimation, we performed meta-analysis to investigate the association between rs861539 polymorphism on XRCC3 gene and the risk of thyroid cancer.

In this study based on results of 11 studies containing 1904 thyroid cancer cases and 2960 controls, we observed an association of XRCC3 rs861539 polymorphism with thyroid cancer risk in the overall analysis under recessive and allelic genetic models, and this result was inconsistent with the previous meta-analysis by Wang \([37]\). The result indicated that the variant T (Met) allele was associated with increased risk of thyroid cancer (OR=1.263, 95% CI (1.091, 1.462), P=0.002). TT genotypes were associated with 1.632-fold (95% CI 1.349 to 1.974, P<0.001) higher risk compared to CC+CT genotypes. No significant association was found between rs861539 polymorphism and thyroid cancer risk, and these results mean that although T allele is the risk factor, CT (heterozygous) genotype is not sufficient for disease induction and development, compared to TT genotype. Since there were obvious heterogeneities among studies under dominant/allelic/overdominant genetic models, then we performed a stratified analysis by ethnicity. Heterogeneities under most genetic models were not reduced through subgroup analysis, which means that ethnicity may not contribute to substantial heterogeneity among the overall meta-analyses.

In the subgroup analysis our results with rs861539 polymorphism show a significant association with thyroid cancer risk among Asians in recessive model (OR=1.964, 95% CI (1.487, 2.595), P<0.001). Additionally, we did not observe an association of XRCC3 rs861539 (Thr241Met) polymorphism with thyroid cancer risk in Allelic model among Caucasians (OR=1.107, 95% CI (0.959, 1.279), P=0.166). These findings above indicate that the effect of XRCC3 rs861539 polymorphism on the risk of thyroid cancer is ethnically different and the rs861539 polymorphism has its obvious effect on the development of thyroid cancer in Asians. However, these results above by subgroup analysis were inconsistent with the previous meta-analysis by Lu \([11]\).

To sum up, our meta-analysis indicates that rs861539 polymorphism may be associated with an increased thyroid cancer risk in overall population, and a tendency for significantly increased thyroid cancer risk in TT (Met/Met) genotype population, and this association was obviously exists in Asians.

Individuals with polymorphisms in XRCC3 rs861539 locus have a potential risk of thyroid cancer, but the carcinogenesis of rs861539 polymorphism to thyroid is still not completely understood. It is largely accepted that ionizing radiation would stimulate DNA damage, which would then induct genomic instability, and previous study indicated that variant genotypes of XRCC3 codon241 are associated with increased DNA damage with increased sensitivity to DNA toxic agents \([38]\).

To our best knowledge, this is the most comprehensive meta-analysis with the largest sample size tried to explore the association between single nucleotide polymorphism (SNP) in the XRCC3 rs861539 (Thr241Met) locus and thyroid cancer risk. Our study had the advantage of including higher numbers of cases and controls and assessment of sensitivity analysis. However, there were still some limitations in this meta-analysis. First, these results are based on unadjusted estimates that lack original data from the included studies, and a more precise analysis should be conducted. Second, the controls were not uniformly defined, and not all the controls from included studies in consistent with Hardy Weinberg equilibrium. Third, Additional functional as well as association studies investigating gene-gene and gene-environment interactions are required to elucidate this issue. Lastly, lack of available data prevented us from performing additional subgroup analyses by age, gender, ionizing radiation and other risk factors. For these limitations, the results should be treated with caution. Certainly, our discovery warrant confirmation by further investigations with larger sample size.

4. Declarations

Abbreviations:

XRCC3 (X-ray repair cross-complementing group 3); TC (thyroid cancer); CBM (China Biology Medicine); CNKI (Chinese National Knowledge Infrastructure); HWE (Hardy Weinberg equilibrium); SNP (single nucleotide polymorphism); NOS (Newcastle–Ottawa quality assessment Scales); ORs (odds ratios); CIs (confidence intervals); RFLP (Restriction fragment length polymorphism); ARMS-PCR: Allele-specific polymerase chain reaction; RecA/Rad51 (recombination protein A).
Ethics approval and consent to participate:

Not applicable.

Consent for publication:

Not applicable.

Availability of data and material:

The datasets used and analysed during the current study available from the published articles (Ref. 12-14, 16-22).

Competing interests:

The authors have declared that no competing interest exists.

Funding:

There were no sources of financial support for this research.

Authors' contributions

Yayun Wu and Yun Ren conceived and designed the study. Zhimin Cao, Kai Zhang, and Xiaoqiang Dong were responsible for the literature selection, data extraction, and statistical analysis. Yayun Wu and Yun Ren wrote the first draft of the manuscript. Qinjing Lv, Bowen Wang, and Wei Yao performed the databases searching. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018,68(6):394-424.

[2] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA: a cancer journal for clinicians, 2016,66(2):115-132.

[3] Wang W, Chang J, Jia B, et al. The Blood Biomarkers of Thyroid Cancer[J]. Cancer Management and Research, 2020,Volume 12:5431-5438.

[4] Pitoia F, Smulever A. Active surveillance in low risk papillary thyroid carcinoma[J]. World J Clin Oncol, 2020,11(6):320-336.

[5] Houten R, Fleeman N, Kotas E, et al. A systematic review of health state utility values for thyroid cancer[J]. Qual Life Res, 2020.

[6] Zhao J Z, Tan X R, Zhao M, et al. Association between the X-ray repair cross-complementing group 1 Arg194Trp polymorphism and thyroid carcinoma susceptibility: A meta-analysis[J]. Genet Mol Res, 2016,15(3).

[7] Howlader N R, Rahman M M, Hossain M A, et al. Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population[J]. Breast Cancer Res Treat, 2020,182(3):739-750.

[8] Pasqualetti F, Gonnelli A, Orlandi P, et al. Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy[J]. Invest New Drugs, 2021.

[9] Shokofeh T, Shima F, Mina E, et al. Association of Thr241Met polymorphisms in XRCC3 gene and risk of differentiated thyroid carcinoma in Iran[J]. CLINICAL BIOCHEMISTRY, 2011,44S(13):S198-S199.

[10] Yu X, Liu H, Wang B, et al. Significant associations between X-ray repair cross-complementing group 3 genetic polymorphisms and thyroid cancer risk[J]. TUMOR BIOLOGY, 2014,35(3):2009-2015.

[11] Lu W, Wu G, Zhang B. Association Between X-Ray Cross-Complementing Group 3 (XRCC3) Thr241Met Polymorphism and Risk of Thyroid Cancer: A Meta-Analysis[J]. MEDICAL SCIENCE MONITOR, 2015,21:3978-3985.

[12] Ni H, Bian JC, Shen Q et al: Genetic polymorphisms of XRCC3 and susceptibility of papillary thyroid carcinoma. Fudan Univ J Med Sci, 2006; 33: 147–52
[13] Akulevich N M, Saenko V A, Rogounovitch T I, et al. Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma[J]. ENDOCRINE-RELATED CANCER, 2009,16(2):491-503.

[14] Siraj A K, Al-Rasheed M, Ibrahim M, et al. RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population[J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008,31(10):893-899.

[15] Wang X, Zhang K, Liu X, et al. Association between XRCC1 and XRCC3 gene polymorphisms and risk of thyroid cancer[J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015,8(3):3160-3167.

[16] Sturgis E M, Zhao C, Zheng R, et al. Radiation response genotype and risk of differentiated thyroid cancer: A case-control analysis[J]. LARYNGOSCOPE, 2005,115(6):938-945.

[17] Bastos H N, Antao M R, Silva S N, et al. Association of Polymorphisms in Genes of the Homologous Recombination DNA Repair Pathway and Thyroid Cancer Risk[J]. THYROID, 2009,19(10):1067-1076.

[18] Fayaz S, Karimmirza M, Tanhaei S, et al. Increased Risk of Differentiated Thyroid Carcinoma with Combined Effects of Homologous Recombination Repair Gene Polymorphisms in an Iranian Population[J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013,14(11):6727-6731.

[19] Yuan K, Huo M, Sun Y, et al. Association between x-ray repair cross-complementing group 3 (XRCC3) genetic polymorphisms and papillary thyroid cancer susceptibility in a Chinese Han population[J]. TUMOR BIOLOGY, 2016,37(1):979-987.

[20] Sarwar R, Mahjabeen I, Bashir K, et al. Haplotype Based Analysis of XRCC3 Gene Polymorphisms in Thyroid Cancer[J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017,42(1):22-33.

[21] Yan L, Li Q, Li X, et al. Association Studies Between XRCC1, XRCC2, XRCC3 Polymorphisms and Differentiated Thyroid Carcinoma[J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016,38(3):1075-1084.

[22] Santos L S, Gomes B C, Bastos H N, et al. Thyroid Cancer: The Quest for Genetic Susceptibility Involving DNA Repair Genes[J]. GENES, 2019,10(5868).

[23] Sangrajrang S, Schmezer P, Burkholder I, et al. The XRCC3 Thr241Met polymorphism and breast cancer risk: a case-control study in a Thai population[J]. Biomarkers, 2007,12(5):523-532.

[24] Talar-Wojnarowska R, Gąsiorowska A, Olakowski M, et al. Analysis of XRCC2 and XRCC3 gene polymorphisms in pancreatic cancer[J]. Biomed Rep, 2016,4(2):236-240.

[25] Kaur J, Sambyal V, Guleria K, et al. Association of XRCC1, XRCC2 and XRCC3 Gene Polymorphism with Esophageal Cancer Risk[J]. Clin Exp Gastroenterol, 2020,13:73-86.

[26] He Y, Penney M E, Negandhi A A, et al. XRCC3 Thr241Met and TYMS variable number tandem repeat polymorphisms are associated with time-to-metastasis in colorectal cancer[J]. PLoS One, 2018,13(2):e192316.

[27] Jacobsen N R, Raaschou-Nielsen O, Nexø B, et al. XRCC3 polymorphisms and risk of lung cancer[J]. Cancer Lett, 2004,213(1):67-72.

[28] Alkasaby M K, Abd E A, Ibrahim I H, et al. Polymorphism of XRCC3 in Egyptian Breast Cancer Patients[J]. Pharmgenomics Pers Med, 2020,13:273-282.

[29] Aboul E A, Khaled I, Khorshied M M, et al. Genetic variations in DNA-repair genes (XRCC1, 3, and 7) and the susceptibility to hepatocellular carcinoma in a cohort of Egyptians[J]. J Med Virol, 2020.

[30] León-Mejía G, Quintana-Sosa M, de Moya H Y, et al. DNA repair and metabolic gene polymorphisms affect genetic damage due to diesel engine exhaust exposure[J]. Environ Sci Pollut Res Int, 2020,27(16):20516-20526.

[31] Su Y, Zhang H, Xu F, et al. DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival[J]. Cell Physiol Biochem, 2015,36(4):1419-1429.

[32] Chai F, Liang Y, Chen L, et al. Association between XRCC3 Thr241Met Polymorphism and Risk of Breast Cancer: Meta-Analysis of 23 Case-Control Studies[J]. Med Sci Monit, 2015,21:3231-3240.

[33] Su C H, Chang W S, Hu P S, et al. Contribution of DNA Double-strand Break Repair Gene XRCC3 Genotypes to Triple-negative Breast Cancer Risk[J]. Cancer Genomics Proteomics, 2015,12(6):359-367.
[34] Chen H J, Chang W S, Hsia T C, et al. Contribution of Genotype of DNA Double-strand Break Repair Gene XRCC3, Gender, and Smoking Behavior to Lung Cancer Risk in Taiwan[J]. Anticancer Res, 2015,35(7):3893-3899.

[35] Guo J, Lv H C, Shi R H, et al. Association between XRCC3 Thr241Met polymorphism and risk of osteosarcoma in a Chinese population[J]. Genet Mol Res, 2015,14(4):16484-16490.

[36] Fan J, Fan Y, Kang X, et al. XRCC3 T241M polymorphism and melanoma skin cancer risk: A meta-analysis[J]. Oncol Lett, 2015,9(5):2425-2429.

[37] Wang C, Ai Z. Association of XRCC1 polymorphisms with thyroid cancer risk[J]. TUMOR BIOLOGY, 2014,35(5):4791-4797.

[38] Soliman A, Zaki N N, Fathy H M, et al. Genetic polymorphisms in XRCC1, OGG1, and XRCC3 DNA repair genes and DNA damage in radiotherapy workers[J]. Environ Sci Pollut Res Int, 2020,27(35):43786-43799.